Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban vs Enoxaparin for VTE Prevention in Total Knee Replacement (RECORD 3)
NCT00361894Phase 3Completed
- Sponsor
- Bayer
- Start
- Feb 2006
- Primary completion
- Jan 2007
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of rivaroxaban in venous thromboembolism (VTE) (2 arms), sponsored by Bayer. Primary endpoint: Composite of Total Venous Thromboembolism. Started Feb 2006; status: completed.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00361894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00361894.